Abciximab: a review and update for clinicians

References

• Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction: description of a new technique and a preliminary report of its application. Circulation30, 654 (1964).
   PubMed Web of Science ®Google Scholar
• Gruentzig A, Kumpe DA. Technique of percutaneous transluminal angioplasty with the Gruentzig balloon catheter. AJR Am. J. Roentgenol.132, 547 (1979).
   PubMed Web of Science ®Google Scholar
• Topol EJ. Bonan R. Jewitt D et al. Use of a direct antithrombin, Hirulog, in place of heparin during coronary angioplasty. Circulation87(5), 1622–1629 (1993).
   PubMed Web of Science ®Google Scholar
• The Benestent Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N. Engl. J. Med.(8)331, 489–495 (1994).
   Google Scholar
• The Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N. Engl. J. Med.(8)331, 496–501 (1994).
   Google Scholar
• The Gianturco-Roubin Intracoronary Stent Investigator Group. Major clinical events after coronary stenting, the multicenter registry of acute and elective gianturco-roubin stent placement. Circulation89, 1126–1137 (1994).
   PubMed Web of Science ®Google Scholar
• Kong DF, Califf RM, Miller DP et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation98, 2829–2835 (1998).
   PubMed Web of Science ®Google Scholar
• Coller BS. 1985, a new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J. Clin. Invest.76, 101–108 (1985).
   PubMed Web of Science ®Google Scholar
• Plow EF, Ginsberg MH. Cellular adhesion: GP IIb/IIIa as a prototypic adhesion receptor. Prog. Hemost. Thromb.9, 117 (1989).
   PubMedGoogle Scholar
• ACC/AHA/SCAI Writing Committee. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline for Percutaneous Intervention. J. Am. Coll. Cardiol.51(2), 172–209 (2008).
   PubMed Web of Science ®Google Scholar
• ACC/AHA Writing Committee. ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction. J. Am. Coll. Cardiol.44, 671–719 (2004).
   PubMedGoogle Scholar
• Montalescot G et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N. Engl. J. Med.344(25), 1895–1903 (2001).
   PubMed Web of Science ®Google Scholar
• Antoniucci D, Rodriguez A, Hempel A et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J. Am. Coll. Cardiol.42(11), 1879–1885 (2003).
   PubMed Web of Science ®Google Scholar
• The ReoPro Readministration Registry Investigators. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation104, 870–875 (2001).
   PubMed Web of Science ®Google Scholar
• Simonton CA, Mark DB, Hinohara T et al. Late restenosis after emergent coronary angioplasty for acute myocardial infarction: comparison with elective coronary angioplasty. J. Am. Coll. Cardiol.11, 698–705 (1988).
   PubMed Web of Science ®Google Scholar
• Neumann FJ, Kastrati A, Schmitt C et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J. Am. Coll. Cardiol.35(4), 915–921 (2000).
   PubMed Web of Science ®Google Scholar
• Karvouni E, Katritsis DG, Ioannidis JP et al. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous interventions. J. Am. Coll. Cardiol.41, 26–32 (701) (2003).
   Google Scholar
• Bakhai A, Stone G, Grines C. Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction. Circulation108, 2857–2863 (2003).
   PubMed Web of Science ®Google Scholar
• McCollam P, Foster D, Reismeyer J. Cost and effectiveness of glycoprotein IIb/IIIa receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am. J. Health-Syst. Pharm.60, (2003).
   PubMedGoogle Scholar
• Coller BS, Peerschke EI, Scudder LE et al. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produced a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J. Clin. Invest.72, 325–338 (1983).
   PubMed Web of Science ®Google Scholar
• Becker RC. Clinical trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease: intravenous agents. UpToDate (2006).
   Google Scholar
• Mager DE, Mascelli MA, Kleiman NS et al. Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. J. Pharmacol. Exp. Ther.307, 969–976 (2003).
   PubMed Web of Science ®Google Scholar
• ReoPro® (abciximab), Package insert. Centocor BV, Leiden, The Netherlands (1997).
   Google Scholar
• The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N. Engl. J. Med.330, 956–961 (1994).
   PubMed Web of Science ®Google Scholar
• The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet349, 1429–1435 (1997).
   PubMed Web of Science ®Google Scholar
• The EPILOG Investigators. Platelet IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N. Engl. J. Med.336, 1689.
   Google Scholar
• Bougie DW, Wilker PR, Wuitschick ED et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GP IIb/IIIa. Blood100(6), 2071–2076 (2002).
   PubMed Web of Science ®Google Scholar
• Dasgupta H, Blankenship JC, Wood GC et al. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am. Heart J.140(2), 206–211 (2000).
   PubMed Web of Science ®Google Scholar
• Merlini PA, Rossi M, Menozzi A et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation109(18), 2203–2206 (2004).
   PubMed Web of Science ®Google Scholar
• Berkowitz SD, Sane DC, Sigmon KN et al.; Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. J. Am. Coll. Cardiol.32(2), 311–319 (1998).
   PubMed Web of Science ®Google Scholar
• Curtis BR, Divgi A, Garritty M et al. Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug. J. Thromb. Haemost2, 985–992 (2004).
   PubMed Web of Science ®Google Scholar
• Reddy MS, Carmody TJ, Kereiakes DJ. Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy. Catheter. Cardiovasc. Interv.52, 486–488 (2001).
   PubMed Web of Science ®Google Scholar
• Nurden P, Clofent-Sanchez G, Jais C et al. Delayed immunologic thrombocytopenia induced by abciximab. Thromb. Haemost.92, 820–828 (2004).
   PubMed Web of Science ®Google Scholar
• Kaluski E, Leitman M, Khiger I et al. Delayed thrombocytopenia following abciximab therapy. Int. J. Cardiovasc. Interv.4, 151–155 (2001).
   PubMedGoogle Scholar
• Huxtable LM, Tafreshi MJ, Rakkar AN. Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists. Am. J. Cardiol.97(3), 426–429 (2006).
   PubMed Web of Science ®Google Scholar
• Sane DC, Damaraju LV, Topol EJ et al. Occurrence of clinical significance of pseudothrombocytopenia during abciximab therapy. J. Am. Coll. Cardiol.36(1), 75–83 (2000).
   PubMed Web of Science ®Google Scholar
• Berkowitz SD, Harrington RA, Rund MM et al. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation95(4), 809–813 (1997).
   PubMed Web of Science ®Google Scholar
• Llevadot J, Coulter SA, Giugliano RP. A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors. J. Thromb. Thrombolysis9(2), 175–180 (2000).
   PubMed Web of Science ®Google Scholar
• Bishara AI, Hagmeyer KO. Acute profound thrombocytopenia following abciximab therapy. the annals of pharmacotherapy. Ann. Pharmacother.34, 924–930 (2000).
   PubMed Web of Science ®Google Scholar
• Keriakes DJ, Essell JH, Abbottsmith CW et al. Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion. Am. J. Cardiol.78, 1161–1163 (1996).
   PubMed Web of Science ®Google Scholar
• Brener SJ, Barr LA, Burchenal JEB et al.; the RAPPORT Investigators. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation98, 734–741 (1998).
   PubMed Web of Science ®Google Scholar
• Rothobaum D, Linnemeier T, Landin R et al. Emergency percutaneous transluminal coronary angioplasty in acute myocardial infarction: a 3-year experience. J. Am. Coll. Cardiol.10, 264–272 (1987).
   PubMed Web of Science ®Google Scholar
• Ellis S, O’Neill W, Bates E et al. Implications for patient triage from survival and left ventricular functional recovery analyses in 500 patients treated with coronary angioplasty for acute myocardial infarction. J. Am. Coll. Cardiol.13, 1251–1259 (1989).
   PubMed Web of Science ®Google Scholar
• Kahn J, Rutherford B, McConahay D et al. Results of primary angioplasty for acute myocardial infarction in patients with multivessel coronary artery disease. J. Am. Coll. Cardiol.16, 1089–1096 (1990).
   PubMed Web of Science ®Google Scholar
• Grines CL, Browne KF, Marco J et al.; Primary Angioplasty in Myocardial Infarction Study Group. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N. Engl. J. Med.328, 685–691 (1993).
   PubMed Web of Science ®Google Scholar
• Gibbons RJ, Holmes DR, Reeder GS et al. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N. Engl. J. Med.328, 685–691 (1993).
   PubMed Web of Science ®Google Scholar
• de Boer MJ, Hoorntje JC, Ottervanger JP et al. Immediate coronary angioplasty versus intravenous streptokinase in acute myocardial infarction: left ventricular ejection fraction, hospital mortality and reinfarction. J. Am. Coll. Cardiol.23, 1004–1008 (1994).
   PubMed Web of Science ®Google Scholar
• Stone GW, Grines CL, Cox DA et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N. Engl. J. Med.346(13), 957–966 (2002).
   PubMed Web of Science ®Google Scholar
• De Luca G, Suryapranata H, Stone GW et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA293(14), 1759–1765 (2005).
   PubMed Web of Science ®Google Scholar
• ACC/AHA/SCAI Writing Committee. ACC/AHA/SCAI guideline update for percutaneous coronary intervention. Circulation113(1), 156–175 (2005).
   Web of Science ®Google Scholar
• Gibson CM, Cannon CP, Murphy SA et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation101, 125–130 (2000).
   PubMed Web of Science ®Google Scholar
• Antman EM, Giugliano RP, Gibson CM et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation99, 2720–2732 (1999).
   PubMed Web of Science ®Google Scholar
• SPEED Investigators. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation101(24), 2788–2794 (2000).
   PubMed Web of Science ®Google Scholar
• Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomized trial. Lancet357(9272), 1905–1914 (2001).
   PubMed Web of Science ®Google Scholar
• ASSENT-3 Investigators. Efficacy and Safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction. Lancet358(9282), 605–613 (2001).
   PubMed Web of Science ®Google Scholar
• Ellis S. European Society of Cardiology Congress. Vienna, Austria 3 September 2007.
   Google Scholar
• Antman EM, Hand M, Armstrong PW et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of st-elevation myocardial infarction. J. Am. Coll. Cardiol.51, 210–247 (2008).
   PubMed Web of Science ®Google Scholar
• Topol EJ, Califf RM, Weisman HF et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for the reduction of clinical restenosis: results at six months. Lancet343(8902), 881–886 (1994).
   PubMed Web of Science ®Google Scholar
• Topol EJ, Ferguson JJ, Weisman HF et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin 3 blockade with percutaneous coronary intervention. JAMA278(6), 479–484 (1997).
   PubMed Web of Science ®Google Scholar
• Van den Brand M, Laarman GJ, Steg PG et al. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial. Eur. Heart J.20(21), 1572–1578 (1999).
   PubMed Web of Science ®Google Scholar
• Simoons ML. Effect of glycoprotein IIb/IIIa receptor blockade on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO IV-ACS randomized trial. Lancet357(9272), 1915–1924 (2001).
   PubMed Web of Science ®Google Scholar
• ACC/AHA UA/NSTEMI 2007. Guideline Revision. J. Am. Coll. Cardiol.50, 1–157 (2007).
   PubMed Web of Science ®Google Scholar
• Kastrati A, Mehilli J, Neumann FJ et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment. JAMA295, 1531–1538 (2006).
   PubMed Web of Science ®Google Scholar
• The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet352(9122), 87–92 (1998).
   PubMed Web of Science ®Google Scholar
• The ERASER Investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis. Circulation100(8), 799–806 (1999).
   PubMed Web of Science ®Google Scholar
• Kastrati A, Mehilli J, Schuhlen H et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N. Engl. J. Med.350(3), 232–238 (2004).
   PubMed Web of Science ®Google Scholar
• Mehilli J, Kastrati A, Schuhlen H et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous elective coronary interventions after treatment with a high loading dose of clopidogrel. Circulation110(24), 3627–3635 (2004).
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert Rev. Cardiovasc. Ther.5(1), 45–55 (2007).
   PubMedGoogle Scholar